Citius Oncology, Stock Buy Hold or Sell Recommendation
| CTOR Stock | 0.94 0.06 6.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Citius Oncology, is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Citius Oncology, given historical horizon and risk tolerance towards Citius Oncology,. When Macroaxis issues a 'buy' or 'sell' recommendation for Citius Oncology,, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Citius Oncology, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Citius Stock, please use our How to Invest in Citius Oncology, guide. Note, we conduct extensive research on individual companies such as Citius and provide practical buy, sell, or hold advice based on investors' constraints. Citius Oncology,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Citius |
Execute Citius Oncology, Buy or Sell Advice
The Citius recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Citius Oncology,. Macroaxis does not own or have any residual interests in Citius Oncology, or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Citius Oncology,'s advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Citius Oncology, Trading Alerts and Improvement Suggestions
| Citius Oncology, generated a negative expected return over the last 90 days | |
| Citius Oncology, has high historical volatility and very poor performance | |
| Citius Oncology, has some characteristics of a very speculative penny stock | |
| Citius Oncology, was previously known as TenX Keane Acquisition and was traded on NASDAQ Exchange under the symbol TENK. | |
| Citius Oncology, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab and LYMPHIR in Cancer Patients with Recurrent Solid Tumors |
Citius Oncology, current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Citius analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Citius analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Citius Oncology, Returns Distribution Density
The distribution of Citius Oncology,'s historical returns is an attempt to chart the uncertainty of Citius Oncology,'s future price movements. The chart of the probability distribution of Citius Oncology, daily returns describes the distribution of returns around its average expected value. We use Citius Oncology, price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Citius Oncology, returns is essential to provide solid investment advice for Citius Oncology,.
| Mean Return | -0.86 | Value At Risk | -10.29 | Potential Upside | 13.75 | Standard Deviation | 6.71 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Citius Oncology, historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Citius Oncology, Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Citius Oncology, or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Citius Oncology,'s price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Citius stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.13 | |
β | Beta against Dow Jones | 2.19 | |
σ | Overall volatility | 6.54 | |
Ir | Information ratio | -0.15 |
Citius Oncology, Volatility Alert
Citius Oncology, is displaying above-average volatility over the selected time horizon. Citius Oncology, is a potential penny stock. Although Citius Oncology, may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Citius Oncology,. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Citius instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Citius Oncology, Fundamentals Vs Peers
Comparing Citius Oncology,'s fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Citius Oncology,'s direct or indirect competition across all of the common fundamentals between Citius Oncology, and the related equities. This way, we can detect undervalued stocks with similar characteristics as Citius Oncology, or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Citius Oncology,'s fundamental indicators could also be used in its relative valuation, which is a method of valuing Citius Oncology, by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Citius Oncology, to competition |
| Fundamentals | Citius Oncology, | Peer Average |
| Current Valuation | 116.23 M | 16.62 B |
| Shares Outstanding | 2 M | 571.82 M |
| Number Of Shares Shorted | 39.42 K | 4.71 M |
| Price To Book | 4.55 X | 9.51 X |
| Market Capitalization | 116.23 M | 19.03 B |
Note: Acquisition by Holubiak Myron Z of 500000 shares of CTOR at 2.15 subject to Rule 16b-3 [view details]
Citius Oncology, Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Citius . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Citius Oncology, Buy or Sell Advice
When is the right time to buy or sell Citius Oncology,? Buying financial instruments such as Citius Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Citius Oncology, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Adviser Favorites Thematic Idea Now
Adviser Favorites
Financial advisors frequently recommend that individuals diversify their investment portfolios with a mix of different types of stocks. These can include blue-chip stocks, growth stocks, and dividend stocks. The Adviser Favorites theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Adviser Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.